Celldex Therapeutics, Inc. (CLDX)

Market Cap	1.41B
Revenue (ttm)	7.56M
Net Income (ttm)	-178.85M
Shares Out	66.39M
EPS (ttm)	-2.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,828,894
Open	20.31
Previous Close	20.35
Day's Range	20.01 - 22.32
52-Week Range	14.40 - 47.00
Beta	1.13
Analysts	Buy
Price Target	50.00 (+135.74%)
Earnings Date	Aug 7, 2025

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, pr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 10, 2008
• Employees: 186
• Stock Exchange: NASDAQ
• Ticker Symbol: CLDX
• Website: https://www.celldex.com

Financial Performance

In 2024, Celldex Therapeutics's revenue was $7.02 million, an increase of 1.99% compared to the previous year's $6.88 million. Losses were -$157.86 million, 11.6% more than in 2023.

Analyst Summary

According to 9 analysts, the average rating for CLDX stock is "Buy." The 12-month stock price target is $50.0, which is an increase of 135.74% from the latest price.

Price Target

$50.0

(135.74% upside)

Analyst Consensus: Buy